Related Experiment Videos
[Economic aspects of therapy for lipid metabolism disorders]
C Pirich1, S Bisovsky, H Sinzinger
1Wilhelm Auerswald--Atheroskleroseforschungsgruppe (ASF) Wien, Osterreichischen Akademie der Wissenschaften ATK.
Insights
Managing hyperlipidemia is crucial for preventing cardiovascular disease. Nutritional therapy is the most cost-effective, while LDL-apheresis is the most effective for severe cases, highlighting the need for cost-effectiveness in lipid management.
Area of Science:
- Cardiovascular Medicine
- Metabolic Disorders
- Health Economics
Context:
- Cardiovascular disease (CVD) prevention relies heavily on managing hyperlipidemia.
- Coronary heart disease (CHD), a major atherosclerosis-related illness, necessitates effective lipid-lowering strategies.
- Healthcare systems face significant medical and economic challenges in addressing hyperlipidemia.
Purpose:
- To evaluate the cost-effectiveness of various hyperlipidemia therapies.
- To compare the financial costs and clinical efficacy of nutritional therapy, dietetic nutritionals, drugs, and LDL-apheresis.
- To inform healthcare policy and patient management regarding lipid-lowering treatments.
Summary:
- A cost-effectiveness analysis was performed for hyperlipidemia treatments, assessing impacts on total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglycerides.
- Nutritional therapy emerged as the most economical option.
- LDL-apheresis, though the most expensive, demonstrated the highest effectiveness and reliability, particularly for severe familial hypercholesterolemia.
Impact:
- Findings underscore the importance of considering cost-effectiveness in therapeutic decisions for hyperlipidemia.
- Highlights the significant role of lifestyle modifications, like nutritional changes, in reducing healthcare expenditure.
- Emphasizes the need for financial regulations in healthcare due to rising medical service costs.
Abstract:
The primary and secondary prevention of cardiovascular diseases and, therefore, the therapy of hyperlipidemia is essential in strategies to lower morbidity and mortality from coronary heart disease (CHD), the most relevant atherosclerosis-associated disease. These programs imply not only a medical but also an economic challenge to our health system. That is why all therapeutic measures have to be evaluated regarding their cost-effectiveness. A cost-effectiveness profile was calculated for all the therapies of hyperlipidemia (nutritional therapy, dietetic nutritionals, drugs and LDL-apheresis) with respect to the following parameters: total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides. The daily costs of all interventional measures are compared to the success rate, whereby an index of daily therapy costs and 1% change per lipid parameter was calculated. Nutritional therapy is by far the cheapest, and LDL-apheresis the most expensive but also the most effective and reliable therapeutic measure. It has to be considered, however, that dietary intervention can be very successful in overnutrition while in rare cases of severe homozygous familial hypercholesterolemia there is no therapeutic alternative to LDL-apheresis. Life-style modifications, such as changing nutritional habits, may contribute towards reducing or removing one or more risk factor(s) (e.g. malnutrition is associated with overweight, hyperlipoproteinemia (HLP), hyperinsulinemia (syndrome X), hyperfibrinogenemia and hypertension). But neither health politicians nor the population seem to be conscious of the fact that life-style changes help to reduce medical expenditure. Considering the fact that nearly every medical service is getting more and more expensive, the need to introduce financial regulations is evident.(ABSTRACT TRUNCATED AT 250 WORDS)